Can a cancer drug make stem cell transplants safer for myelofibrosis patients?
NCT ID NCT04384692
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This study tests whether giving the drug ruxolitinib before, during, and after a donor stem cell transplant can prevent graft-versus-host disease (GVHD) in people with myelofibrosis. GVHD is a serious complication where donor cells attack the patient's body. The trial involves 53 adults with intermediate- or high-risk myelofibrosis. Ruxolitinib is already used to reduce symptoms like an enlarged spleen and night sweats, and researchers hope it will also lower GVHD risk and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib
What this could lead to
If successful, this approach could reduce severe graft-versus-host disease and improve survival and quality of life for myelofibrosis patients undergoing stem cell transplant.
What could go wrong
This is a small Phase 2 trial with only 53 participants, so results may not apply to all patients. Ruxolitinib can cause side effects like infections and low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.